Business context and reporting period
Important identity discrepancy: The supplied filing is AspenBio Pharma, Inc.’s Form 10-Q for the quarter ended September 30, 2011—not a filing by Riot Platforms, Inc. The summary below reflects the filing text provided.
AspenBio was developing the AppyScore acute-appendicitis diagnostic and animal-health products, while reporting limited antigen-product sales. The financial statements are unaudited; the nine-month period ended September 30, 2011 is compared with the same period in 2010.
Financial and operating results
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Sales | $22,381 | $80,483 | $175,019 | $281,748 |
| Gross profit (loss) | $21,999 | ($69,884) | $159,061 | $31,855 |
| Operating loss | ($3,011,209) | ($3,027,295) | ($8,530,675) | ($10,249,708) |
| Net loss | ($3,063,450) | ($3,052,050) | ($8,656,576) | ($10,345,736) |
| Net loss per share | ($0.38) | ($0.38) | ($1.08) | ($1.33) |
Gross margin was about 98% in Q3 2011 versus a gross loss margin of about 87% in Q3 2010; for the nine months, it was about 91% versus 11%. The improvement largely reflected prior-year inventory write-downs and the absence of fixed production costs in 2011, rather than significant sales growth.
For the first nine months, selling, general and administrative expense was $4.37 million, down 26%; research and development was $4.37 million, essentially flat. Q3 R&D rose 58% to $1.65 million, including $507,000 of AppyScore pilot-trial costs. The nine-month loss narrowed, while the Q3 net loss was roughly unchanged year over year.
Cash, liquidity and debt
- At September 30, 2011, cash and cash equivalents were $2.40 million and short-term investments were $2.39 million, totaling $4.79 million. Working capital was $2.02 million, compared with $12.31 million of current assets at year-end 2010.
- Cash used in operating activities was $6.41 million for the first nine months, versus $8.57 million in 2010. Cash and cash equivalents fell $6.51 million from year-end 2010.
- Total notes and other obligations were $2.90 million, including $439,574 current. Mortgage notes were $2.57 million. The bank mortgage portion has an estimated $1.61 million principal balance due in June 2013.
- Assets were $9.97 million and total liabilities were $6.35 million at September 30, 2011. Stockholders’ equity was $3.61 million.
Material changes versus the prior period
- Nine-month sales declined 38%, primarily because the company had suspended antigen production to redirect resources to product development.
- Operating loss improved by $1.72 million over nine months, helped by lower SG&A and lower cost of sales. Reduced stock-based compensation and public-company costs contributed to the SG&A decline.
- Operating cash use declined by $2.16 million, but liquidity contracted substantially and the company reported no financing proceeds in 2011 through September. In 2010, it raised about $9.12 million net from a stock offering.
- A one-for-five reverse stock split took effect July 29, 2011; share and per-share data in the filing are retroactively adjusted.
Outlook, risks and unusual items
- Management expected continued operating losses in the near term and stated that additional capital would likely be needed within 12 months. It believed working capital would cover estimated needs for the remainder of 2011 and cited a filed shelf registration statement and other funding alternatives. The filing does not provide a clear quantified financing plan or assurance of funding.
- Management expected 2011 R&D spending to be in line with 2010 and capital expenditures of $50,000–$100,000. Product development, testing, patent work and commercialization could continue to require substantial spending.
- The 2010 ELISA-based AppyScore trial showed lower specificity than the prior study; the company decided not to submit that trial’s results for FDA clearance. It was conducting cassette-based pilot studies and expected, subject to favorable results, to start a pivotal trial sometime in 2012. FDA clearance, trial success and commercialization were uncertain.
- Novartis Animal Health requested repayment of a remaining $900,000 milestone after a pilot study did not meet specified success criteria. The company was negotiating resolution and expected payments that included the $900,000 plus cost-sharing amounts; the $900,000 was reclassified as a current accrued liability.
- Two securities-related lawsuits concerning AppyScore allegations had amended complaints and pending motions to dismiss as of the filing; a shareholder derivative action remained stayed. The company said it intended to defend the claims.
- Other disclosed risks include clinical and regulatory delays or failure, dependence on external financing and collaborators, product acceptance and reimbursement, manufacturing and supplier issues, intellectual-property challenges, and competition. The company reported no income-tax benefit on its loss because realization was not considered more likely than not.
Most important facts for investors to verify
- Confirm the issuer and filing: the source is AspenBio Pharma, not Riot Platforms.
- Check subsequent developments in financing, cash runway, and the company’s ability to fund operations beyond 2011.
- Verify the outcome and payment terms of the Novartis dispute, including the $900,000 milestone and any additional cost-sharing obligation.
- Review AppyScore pilot results, FDA interactions, and whether a pivotal trial began as anticipated.
- Track the securities litigation and any potential financial exposure; the supplied text does not quantify a probable loss.